This article was originally published in The Tan Sheet
Botanical dietary supplements with a safe history may not require the same level of toxicity testing as synthetic pharmaceutical drugs, according to research published in the February American Journal of Clinical Nutrition. Misidentification, production errors, contamination or poor manufacturing processes are associated with most incidences of toxicity in supplements, according to Richard B. van Breemen at the University of Illinois-Chicago National Institutes of Health Center for Botanical Dietary Supplements Research. Additionally, botanical-drug interactions can be a source of toxicity, including formation of electrophilic metabolites, allergic reactions, botanical-induced autoimmune reactions, or specific systemic or organ-specific reactions, the researchers say. However, most toxicity can be prevented by sound agricultural and manufacturing practices and by applying existing toxicity tests similar to those used in drug development or new toxicity assays under development based on proteomics, genomics or metabolomics, van Breeman et al. say...
You may also be interested in...
Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.